Mankind Pharma
- ISIN
- INE634S01028
- Instrument key
- NSE_EQ|INE634S01028
as of 21/11/2026, 2:32:43 pm
- Open
- ₹2,627.00
- Day high
- ₹2,669.90
- Day low
- ₹2,620.20
- Prev. close
- ₹2,629.00
- Volume
- 4.56 L
- VWAP
- ₹2,646.06
02/Price history
Price chart
1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
No candles for this range
Intraday candles are empty outside market hours — pick a longer range.
Candle data0 rows of open, high, low, close and volumeShowHide
No candles in this range
03/Valuation & returns
Key ratios vs sector
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 208%
Price ÷ book value per share
Worse than sector by 48%
Net income ÷ total assets
Better than sector by 557%
Net income ÷ shareholders' equity
Better than sector by 3290%
EBIT ÷ capital employed
Worse than sector by 5%
Liquid assets ÷ current liabilities
Worse than sector by 85%
Enterprise value ÷ EBITDA
Worse than sector by 15%
04/Business
About the company
Sector: Pharmaceuticals
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
- ₹1,09,870 Cr
- $12.21B
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Standalone income statement
Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.
- Revenue · Mar 2026
- ₹10,747 Cr+7.46% vs Mar 2025
- Net profit · Mar 2026
- ₹2,038 Cr+14.09% vs Mar 2025
- Operating margin
- 21.5%was 21.5%
- Revenue CAGR · 4p
- 9.0%profit 17.7% · op 14.0%
| Revenue | 10,747 | 10,001 | 8,900 | 8,290 |
|---|---|---|---|---|
| Revenue growthreported | 7.5% | 12.4% | 7.4% | — |
| Operating profit | 2,315 | 2,147 | 2,185 | 1,563 |
| Operating profit growthreported | 7.8% | -1.8% | 39.8% | — |
| Operating marginderived | 21.5% | 21.5% | 24.6% | 18.9% |
| Net profit | 2,038 | 1,786 | 1,876 | 1,248 |
| Net profit growthreported | 14.1% | -4.8% | 50.3% | — |
| Net marginderived | 19.0% | 17.9% | 21.1% | 15.1% |
| EPS — basic₹/share, annual | 49.37 | 44.22 | 46.84 | 31.16 |
Figures in ₹ crore. Margin rows are computed from the reported values.
Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
| Revenue | 10,421 | 9,507 | 8,629 | 8,127 |
|---|---|---|---|---|
| Other Income | 326 | 493 | 271 | 163 |
| Total Revenue | 10,747 | 10,001 | 8,900 | 8,290 |
| Total Expenses | 8,326 | 7,854 | 6,715 | 6,727 |
| Profit Before Tax | 2,315 | 2,147 | 2,185 | 1,563 |
| Tax | 277 | 422 | 413 | 315 |
| Profit After Tax | 2,038 | 1,725 | 1,773 | 1,248 |
| EPS - Basic | 49.37 | 44.22 | 46.84 | 31.16 |
| EPS - Diluted | 49.30 | 44.13 | 46.77 | 31.16 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Standalone balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
- Total assets · Mar 2026
- ₹24,625 Cr+0.68% YoY
- Total liabilities
- ₹8,228 Cr
- Net worth
- ₹16,397 Cr
- Liabilities ÷ assets
- 33.4%lower means a lighter balance sheet
| Total assets | 24,625 | 24,458 | 11,516 | 9,371 |
|---|---|---|---|---|
| Total liabilities | 8,228 | 10,136 | 1,814 | 1,587 |
| Net worthderived | 16,397 | 14,323 | 9,703 | 7,784 |
| Liabilities ÷ assetsderived | 33.4% | 41.4% | 15.7% | 16.9% |
| Asset growthderived | 0.7% | 112.4% | 22.9% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
| Non-Current Assets | 20,439 | 19,738 | 5,887 | 5,854 |
|---|---|---|---|---|
| Current Assets | 4,186 | 4,721 | 5,630 | 3,517 |
| Total Assets | 24,625 | 24,458 | 11,516 | 9,371 |
| Current Liabilities | 5,473 | 4,959 | 1,617 | 1,419 |
| Net Current Asset | -1,287 | -238 | 4,013 | 2,098 |
| Non-Current Liabilities | 2,755 | 5,177 | 197 | 168 |
| Equity Capital | 16,397 | 14,323 | 9,703 | 7,784 |
| Total Equity & Liabilities | 24,625 | 24,458 | 11,516 | 9,371 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Standalone cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
- Operating · Mar 2026
- ₹2,752 Cr+17.10% YoY
- Investing
- -₹388 Cr
- Financing
- -₹2,477 Cr
- Free cash flow
- ₹2,364 Croperating + investing
| Operating activities | 2,752 | 2,350 | 1,736 | 1,799 |
|---|---|---|---|---|
| Operating changereported | 17.1% | 35.4% | -3.5% | — |
| Investing activities | -388 | -12,114 | -1,665 | -1,041 |
| Investing changereported | 96.8% | -627.5% | -60.0% | — |
| Financing activities | -2,477 | 9,817 | -5 | -710 |
| Financing changereported | -125.2% | 207637.0% | 99.3% | — |
| Net cash flowderived | -113 | 52 | 66 | 48 |
| Free cash flowoperating + investing | 2,364 | -9,764 | 71 | 758 |
Figures in ₹ crore.
Full annual line itemsProfit before tax through closing cash balanceShowHide
| Profit before tax | 2,315 | 2,231 | 2,326 | 1,563 |
|---|---|---|---|---|
| Income before WC changes | 3,046 | 2,703 | 2,490 | 1,790 |
| Change in Assets | -139 | -186 | -584 | 428 |
| Change in Liabilities | 319 | 305 | 250 | -134 |
| Change in WC | 180 | 118 | -333 | 294 |
| Cash flow from Operations | 2,752 | 2,350 | 1,736 | 1,799 |
| Cash flow from Investing | -388 | -12,114 | -1,665 | -1,041 |
| Cash flow from Financing | -2,477 | 9,817 | -5 | -710 |
| Total Cash Flow | -113 | 52 | 66 | 48 |
| Cash (Start of the year) | 201 | 212 | 145 | 86 |
| Cash (End of the year) | 88 | 201 | 212 | 134 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Corporate actions
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
No corporate actions on record
10/Comparison
Peers & competitors
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Company news
Articles published in the last seven days, paginated by the provider.
No news in the last seven days
Company news is available for a rolling one-week window.